Literature DB >> 17519781

Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.

Lorenzo G Gallon1, Johan Winoto, Darshika Chhabra, Michele A Parker, Joseph R Leventhal, Dixon B Kaufman.   

Abstract

BACKGROUND: It is not known how different steroid-free immunosuppressive combinations affect long-term kidney transplant function in recipients of simultaneous kidney and pancreas transplant (SPK). Here, we sought to evaluate, in SPK recipients, the impact on long-term renal allograft function of two Tac-based prednisone-free maintenance immunosuppressive protocols: tacrolimus (Tac)/mycophonelate mofetil (MMF) versus Tac/ sirolimus (SRL).
METHODS: In this single-center, retrospective, sequential study, we analyzed 59 SPK transplant patients with at median follow up of 5 years. All patients received induction therapy with thymoglobulin and maintenance immunosuppression with Tac/MMF (n=22) or Tac/SRL (n=37). There were no differences between the two groups in regards to age, gender, race, panel reactive antibodies, degree of mismatch, donor age, incidence of delay graft function, and Tac trough levels at different time points after transplantation.
RESULTS: Kaplan-Meier patient survival at 6 years after transplantation was not statistically different between the two groups. Rate of ACR was similar. Kidney survival, even if not statistically significant, was better in the Tac/MMF group than in the Tac/SRL (90.7% vs. 70.7%, P=0.09). The slope of glomerular filtration rate decline per month at 5 years after transplantation was not statistically different between the two groups. Both groups had the same decline over time in glomerular filtration rate of 0.40+/-0.06 mL/min/1.73/month. Pancreas survival at 6 years after transplantation was 100% in both treatment groups.
CONCLUSIONS: Our data suggest that, in SPK recipients, long-term kidney allograft survival and function are not statistically different. A trend toward an increased rate of renal allograft loss was found in the Tac/SRL-treated group.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17519781     DOI: 10.1097/01.tp.0000264189.58324.91

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Ten-year outcome after rapid discontinuation of prednisone in adult primary kidney transplantation.

Authors:  Michael D Rizzari; Thomas M Suszynski; Kristen J Gillingham; Ty B Dunn; Hassan N Ibrahim; William D Payne; Srinath Chinnakotla; Erik B Finger; David E R Sutherland; Raja Kandaswamy; John S Najarian; Timothy L Pruett; Aleksandra Kukla; Richard Spong; Arthur J Matas
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 8.237

Review 2.  Immunosuppression in simultaneous pancreas-kidney transplantation: progress to date.

Authors:  Raymond L Heilman; Marek J Mazur; K Sudhakar Reddy
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

3.  Influence of donor- and recipient-specific factors on the postoperative course after combined pancreas-kidney transplantation.

Authors:  Peter Thomas Fellmer; Andreas Pascher; Andreas Kahl; Frank Ulrich; Katharina Lanzenberger; Konstanze Schnell; Sven Jonas; Stefan G Tullius; Peter Neuhaus; Johann Pratschke
Journal:  Langenbecks Arch Surg       Date:  2010-01       Impact factor: 3.445

Review 4.  Minimization of steroids in kidney transplantation.

Authors:  Arthur J Matas
Journal:  Transpl Int       Date:  2008-07-24       Impact factor: 3.782

5.  Dissociation between peripheral blood chimerism and tolerance to hindlimb composite tissue transplants: preferential localization of chimerism in donor bone.

Authors:  Dina N Rahhal; Hong Xu; Wei-Chao Huang; Shengli Wu; Yujie Wen; Yiming Huang; Suzanne T Ildstad
Journal:  Transplantation       Date:  2009-09-27       Impact factor: 4.939

6.  Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits.

Authors:  L Li; A Chang; M Naesens; N Kambham; J Waskerwitz; J Martin; C Wong; S Alexander; P Grimm; W Concepcion; O Salvatierra; M M Sarwal
Journal:  Am J Transplant       Date:  2009-05-13       Impact factor: 8.086

Review 7.  Steroid elimination-who, when, how?

Authors:  A J Matas
Journal:  Transplant Proc       Date:  2008-12       Impact factor: 1.066

Review 8.  Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result.

Authors:  Titte R Srinivas; Herwig-Ulf Meier-Kriesche
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

9.  Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years.

Authors:  G Ciancio; J Sageshima; L Chen; J J Gaynor; L Hanson; L Tueros; E Montenora-Velarde; C Gomez; W Kupin; G Guerra; A Mattiazzi; A Fornoni; A Pugliese; D Roth; M Wolf; G W Burke
Journal:  Am J Transplant       Date:  2012-09-04       Impact factor: 8.086

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.